All News

The expertise of health system specialty pharmacists, combined with better adherence and better affordability, leads to better patient outcomes.

Paying for these new therapies, that may be curative for patients, remains a challenge.

“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.

Researchers aimed to evaluate the efficacy of the OpenAI technology and offer guidance into its future implementation within health care services.

From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.

Recent research on COVID-19 vaccination shows that vaccines help fight variants, led to lower cases among children in California, and that boosters provide longer lasting protection.

Researchers addressed the wage gaps in specific pharmacy settings in relation to big chain retail pharmacy mergers.

Don’t miss out on the latest pharmacy insights in the Drug Topics April issue.

Check out these important FDA updates from the month of April 2024.

A Q&A with Karen Fancher, PharmD, associate professor of pharmacy practice at Duquesne University School of Pharmacy, on applying ethical principles to manage complex situations in oncology pharmacy.

WHIM syndrome is characterized by low levels of neutrophils and lymphocytes in the blood due to dysfunction in the CXCR4 receptor, which results in serious and frequent infections.

The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.

In case you missed it, this week we had news about bird flu, remote continuous glucose monitoring, new atrial fibrillation care initiatives, and more.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of April 22.

Continuous glucose monitors (CGMs) empower patients with diabetes to take a more active role in managing their condition, but without proper training, many of these advantages become limited.

Fidanacogene elaparvovec-dzkt (Beqvez) is a 1 time treatment that allows patients with hemophilia B to produce factor IX themselves.

US health officials are growing increasingly worried about rising syphilis cases and have begun creating framework to slow down the spread.

The clinical manifestations of shingles can be divided into 3 phases.

Check out these featured Drug Topics expert interviews from April 2024.

A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.

Amneal Pharmaceuticals said its generic naloxone hydrochloride nasal spray is now available in the US following FDA approval.

Despite a wealth of knowledge, pharmacists are frequently not consulted as part of the decision-making team in atrial fibrillation management.

A new study found that cloud-based CGM monitoring services provided statistically significant improvements in high time above range, time in range, and average glucose.

With expertise through antimicrobial stewardship experience, researchers believe antimicrobial stewardship pharmacists are vital in assisting diagnostic stewardship.

A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.

Check out these top featured stories from Drug Topics in April 2024.

By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Collecting smell and taste scores from individuals with and without a history of COVID-19, researchers found significantly lower scores for smell in COVID-19-diagnosed individuals.